ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ONCOLYTICS BIOTECH INC director Stephen C. Glover received a grant of 96,000 stock options. The options have an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026, and expire on June 1, 2036.
The options vest in three equal annual installments starting on June 1, 2027, contingent on Mr. Glover’s continued service or employment. This is a compensation-related award rather than an open-market purchase or sale of common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Glover Stephen C.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 96,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 96,000 shares (Direct, null)
Footnotes (1)
- The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Key Figures
Options granted: 96,000 options
Exercise price: $1.06 per share
Underlying shares: 96,000 common shares
+3 more
6 metrics
Options granted
96,000 options
Stock option award to director Stephen C. Glover
Exercise price
$1.06 per share
Equal to Nasdaq closing price on June 1, 2026
Underlying shares
96,000 common shares
Shares issuable upon exercise of options
Expiration date
June 1, 2036
Option term end date
Vesting schedule
3 equal annual installments
First tranche vests June 1, 2027
Shares after transaction
96,000 derivative securities
Total stock options held following grant
Key Terms
Stock Option, exercise price, vests in three equal annual installments, Nasdaq Capital Market
4 terms
Stock Option financial
"security_title: Stock Option"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"The exercise price is equal to the closing price of the Issuer's common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in three equal annual installments financial
"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027"
Nasdaq Capital Market financial
"closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
FAQ
What did Stephen C. Glover acquire in the latest ONCY Form 4 filing?
Stephen C. Glover received a grant of 96,000 stock options in ONCOLYTICS BIOTECH INC. These options give him the right to buy common shares at a fixed exercise price as part of his compensation, rather than reflecting an open-market trade.
What is the exercise price of Stephen C. Glover’s ONCY stock options?
The exercise price of the granted options is $1.06 per share. This price equals the closing price of ONCOLYTICS BIOTECH INC common stock on the Nasdaq Capital Market on the grant date of June 1, 2026, according to the filing footnote.
How do Stephen C. Glover’s ONCY stock options vest over time?
The 96,000 stock options vest in three equal annual installments beginning June 1, 2027. Each year, one-third becomes exercisable, provided Mr. Glover continues his service or employment with ONCOLYTICS BIOTECH INC on each scheduled vesting date.
When do Stephen C. Glover’s ONCY stock options expire?
The granted stock options expire on June 1, 2036, giving a ten-year term from the grant date. After that expiration date, any unexercised options will lapse and can no longer be used to purchase ONCOLYTICS BIOTECH INC common shares.
Does the ONCY Form 4 show a market purchase or sale by Stephen C. Glover?
The Form 4 reports a grant of stock options, not a market purchase or sale. The transaction code “A” indicates a grant or award, which is a compensation event rather than an open-market trade of ONCOLYTICS BIOTECH INC common shares.